F. Meis ant Spiess

56 SCIENTIFIC SESSIONS September 9-12 | M-314 Geographic Distribution and Co-Morbidities of Cryptococcal Meningitis in the U.S., 1997-2009

V. Pyrgos, A. E. Seitz , R. Prevots, P. R. Williamson; NIH, Bethesda, MD. M-315

Electronic Surveillance of Invasive Fungal Diseases in Hema- tology-Oncology Patients Using Natural Language Processing of Computed Tomography Reports: Towards Real-Time Prospective Surveillance

M. Ananda-Rajah

1 , D. Martinez 2 , H. Suominen 3 , K. Thursky, FRACP 4 , M. Slavin, FRACP 4 , L. Cavedon 2 ; 1 Alfred Hlth., Melbourne, Australia, 2 NICTA, Melbourne, Australia, 3 NICTA, Canberra, Australia, 4 Melbourne Hlth., Melbourne, Australia. M-316 Molecular Epidemiology and Fluconazole Susceptibility of Candida glabrata Candidemia at a University Affiliated Medical Center

N. D. Beyda

1,2 , A. Kilic Scientist 1 , M. J. Alam 1 , T. M. Lasco 2 , K. W. Garey 1,2 ; 1 Univ. of Houston Coll. of Pharmacy, Houston, TX, 2 St. Luke’s Episcopal Hosp., Houston, TX. M-317 Candidemia in Internal Medicine Wards iIMW: Epidemiol- ogy, Time to Initiate Antifungal Treatment and Outcome

M. Bassetti

1 , E. Righi 1 , E. Nicco 2 , L. Taramasso 2 , C. Viscoli 2 ; 1 Santa Maria Misericordia Hosp., Udine, Italy, 2 San Martino Hosp., Genova, Italy. M-318 National Surveillance of Fungemia in Denmark 2010-11

M. C. Arendrup, Danish Fungaemia Study Group; Statens Serum Inst., Copenhagen, Denmark.

M-319 Continued Increase of Azole Resistance in Aspergillus fumiga- tus Af in Dutch Hospitals D. Versteeg, E. Snelders, T. Rijs, BSc - research, W. Melchers, P. Verweij; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. M-320 Development of Resistance to Agricultural Azole Antifungal Compounds: Emergence of Multidrug Cross-Resistance Among Human Fungal Pathogens Candida, Cryptococcus and Aspergillus I. Faria-Ramos 1 , S. Farinha 1 , P. Tavares 1 , J. Maia 1 , E. Ricardo 1,2 , I. M. Miranda 1,2 , C. Pina-Vaz 1,2,3 , A. G. Rodrigues 1,2,3 ; 1 Univ. of Porto, Oporto, Portugal, 2 Cardiovascular Res. Dev. Unit, Faculty of Med., Univ. of Porto, Porto, Portugal, 3 Hosp. S. João, Porto, Portugal. M-321 Population-Based Program of Aspergillus spp. Antifungal Resistance in Spain FILPOP STUDY A. Alastruey-Izquierdo 1 , E. Mellado 1 , T. Pelaez 2 , J. Peman 3 , S. Zapico 4 , M. Alvarez 5 , M. Cuenca-Estrella 1 , FILPOP Study Group; 1 Centro Nacio- nal de Microbiologia, ISCIII, Majadahonda. Madrid, Spain, 2 Hosp. Gregorio Marañón, Madrid, Spain, 3 Hosp. La Fe, Valencia, Spain, 4 Hosp. de Donostia, Guipuzcoa, Spain, 5 Hosp. Central de Asturias, Oviedo, Spain. M-322 Epidemiology of Otomycosis in a Large Teaching Hospital Over a 24-Year Period: Is There Any Difference Between Adult and Pediatric Patients? T. Peláez, S. Álvarez-Pérez, L. Alcalá, B. Gama, BSc, F. Romero, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. M-323 Emerging Trends in Candidemia by C. glabrata: A Better Out- come in a Worse Setting Withdrawn M-324 Influence of Voriconazole VRC on Survival Outcome of Trichosporonemia: Result Epidemiological Study in Japan I. Tokimatsu, H. Kushima, S. Toba, J. Kadota, Japan Trichosporonosis Study Group; Oita Univ. Faculty of Med., Yufu, Japan. M-325 Risk Factors and Epidemiology of Candidemia by Candida guilliermondii

Y. Yamagishi, H. Mikamo; Aichi Med. Univ., Aichi, Japan. M-326

The Defined Daily Dose DDD of Micafungin Usage Didn’t Affect Incidence of Candida parapsilosis Candidemia at Tertiary Hospital in Japan Y. Hirai, S. Asahata, Y. Ainoda, H. Konishi, K. Okada, T. Fujita, K. Totsuka; Tokyo Women’s Med. Univ., Tokyo, Japan. M-327 Species Distribution and Susceptibility Profile of Yeasts Isolated from Blood Cultures: Preliminary Results of a Multi- center Study for Latin America

S. Córdoba

1 , M. Melhem 2 , M. Dolande 3 , A. Puimé 4 , G. Martínez 5 , S. Zurita 6 , M. Cuenca-Estrella 7 , J. Rodríguez-Tudela 7 , J. Gabastou 8 , RLN; 1 INEI, Buenos Aires, Argentina, 2 IAL, SP, Brazil, 3 INHRR, Caracas, Venezuela, Bolivarian Republic of, 4 DLSP, Montevideo, Uruguay, 5 IPK, LH, Cuba, 6 INS, Lima, Peru, 7 ISC III, Majadahonda, Spain, 8 PAHO, SJO, Trinidad and Tobago. M-328 Investigation on Isolation of Trichosporon Species in Clinical Practice

Y. Yamagishi

1 , N. Kawasumi 1 , M. Hagihara 1 , T. Sugita 2 , H. Mikamo 1 ; 1 Aichi Med. Univ., Aichi, Japan, 2 Meiji Pharmaceutical Univ., Tokyo, Japan. M-329 Effect of Statin Use on the Outcomes of Adults with Candidemia G. Cuervo, C. Garcia-Vidal, M. Nucci, F. Puchades, M. Fernandez-Ruiz, A. Mykietiuk, A. Manzur, C. Gudiol, J. Peman, J. Ayats, J. Carratala; Hosp. de Bellvitge, Barcelona, Spain. M-330 New CLSI Clinical Breakpoints CBPs and Epidemiological Cutoff Values ECVs Applied to Characterize Resistance R in the SENTRY Antifungal Surveillance Program 2010-2011 M. A. Pfaller, S. A. Messer, R. N. Jones, M. Castanheira; JMI Lab., N Liberty, IA. M-331 In Vitro Activity of Isavuconazole against Cryptococcus Isolates: A Pooled Analysis from 3 Studies

J. I. Smart

1 , M. E. Jones 2 , L. L. Kovanda, NA 1 ; 1 Astellas Pharma Global Dev., Inc, Deerfield, IL, 2 Basilea Pharmaceutica Intl. Ltd., Basel, Switzerland. M-332 In Vitro Activity of Isavuconazole against a Worldwide Col- lection of 237 Aspergillus Section Terrei Isolates and Compared with 7 Other Aspergillus Active Antifungal Drugs Tested with EUCAST and CLSI Methodology

J. F. Meis ant

1,2 , J. W. Mouton 2 , J. P. Bouchara 3 , A. Chakrabarti 4 , P. Gaustad 5 , J. V. Guinea-Ortega 6 , J. Houbraken 7 , R. A. Samson 7 , K. Grif 8 , C. Lass-Floerl 9 , C. H. Klaassen 1 ; 1 Canisius-Wilhelmina Hosp., Nijmegen, Netherlands, 2 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3 Univ. Angers, Angers, France, 4 Postgrad. Inst. Med.Res., Chandigarh, India, 5 Univ. Hosp. Oslo, Oslo, Norway, 6 Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain, 7 CBS-KNAW Fungal Biodiversity Ctr., Utrecht, Nether- lands, 8 Med. Univ. Innsbruck, Innsbruck, Austria, 9 Med. Univ. Innsbruck, Innsbruck, Austria. 57 SUNDAY SCIENTIFIC SESSIONS Final Program M-333 Absence of Pneumocystis DHPS Mutants in Brittany, Western France S. Le Gal 1 , F. Gangneux 2 , C. Damiani 3 , M. Virmaux 1 , A. Totet 3 , J. Gangneux 2 , G. Nevez 1 ; 1 Univ. de Brest, Brest, France, 2 Univ. de Rennes, Rennes, France, 3 Univ. de Picardie, Amiens, France. M-334 In Vitro Activity of Micafungin Compared with Five other Antifungal Agents against 273 Prospectively Collected Clinical Aspergillus Isolates from The Netherlands I. Curfs 1 , P. J. Haas. PhD 2 , M. Wolfhagen 3 , K. Verduin 4 , C. Bens 1 , C. H. Klaassen 1 , J. F. Meis 1,5 , Dutch Mica Study Group; 1 Canisius-Wilhelmina Hosp., Nijmegen, Netherlands, 2 Univ. Med. Ctr. Utrecht, Utrecht, Nether- lands, 3 Isala Hosp., Zwolle, Netherlands, 4 PAMM, Veldhoven, Netherlands, 5 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. M-335 Investigation of Primary Clinical Samples of Immunocom- promised Patients, Azole Resistant Clinical and Environmental Isolates for Aspergillus Fumigatus Cyp51A Key Mutations Using Sensitive PCR Assays and Consecutive DNA Sequence Analysis

B. Spiess

1 , M. Reinwald 1 , S. J. Howard 2 , U. Gross 3 , O. Bader 3 , P. M. Rath 4 , W. Seifarth 1 , S. Will, TA 1 , M. Lauten 5 , W. K. Hofmann 1 , D. Buchheidt 1 ; 1 Mannheim Univ. Hosp., 3rd Dept. of Internal Med., Mannheim, Germany, 2 Univ. of Liverpool, Translational Med., Liverpool, United Kingdom, 3 Inst. of Med. Microbiol., Göttingen Univ. Hosp., Göttingen, Germany, 4 Inst. of Med. Microbiol., Essen Univ. Hosp., Essen, Germany, 5 Pediatric Hematolo- gy and Oncology, Univ. Hosp. Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. M-336 Molecular Epidemiology of Cryptococcosis in Thailand Re- vealed a Greater Genetic Diversity as Known Previously and the Presence of the Low Virulent Vancouver Island Outbreak

C. gattii Genotype VGIIb